Aurinia Pharmaceuticals Inc.

NASDAQ•AUPH

CEO: Mr. Peter S. Greenleaf M.B.A.

セクター: Healthcare

業種: Biotechnology

上場日: 2014-09-03

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

連絡先情報

118 Avenue , 14315, Suite 140, Edmonton, AB, T5L 4S6, Canada

250-744-2487

www.auriniapharma.com

時価総額

$1.91B

PER (TTM)

6.7

17.5

配当利回り

52週高値

$16.54

52週安値

$6.83

52週レンジ

78%

順位56Top 81.7%

2.5

F-Score

改良版 Piotroski 分析

10年ファンダメンタル

弱い • 2.5 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2016-2025

財務ダッシュボード

Q4 2025 データ

売上高

$77.11M+0.00%

直近4四半期の推移

EPS

$1.58+0.00%

直近4四半期の推移

フリーCF

$44.50M+0.00%

直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

LUPKYNIS Net Sales Increase Net product sales reached $271.3M USD in 2025, marking a strong 25% increase compared to $216.2M USD reported in 2024.

Operating Cash Flow Surges Cash flows from operating activities were $135.7M USD in 2025, showing a 206% increase from $44.4M USD generated during the prior year.

Net Income Rebounds Strongly Net income for 2025 was $287.2M USD, a substantial positive swing from the $5.752M USD net income recorded in 2024.

Restructuring Costs Decline Restructuring expense dropped significantly to $1.6M USD in 2025, down from $23.1M USD incurred in 2024 following prior year efforts.

リスク要因

Dependency on LUPKYNIS Success Business success remains substantially dependent on commercializing LUPKYNIS; competition limits potential growth of net product sales.

Patent Litigation Exposure Filed complaints against generic manufacturers alleging patent infringement; litigation costs expected to protect 2037 Patents covering LUPKYNIS.

Reimbursement Policy Uncertainty Commercial prospects for LUPKYNIS may be limited if subject to unfavorable pricing regulations or restrictive third-party coverage policies.

Product Liability Lawsuits Risk Facing potential product liability lawsuits due to severe adverse reactions in LN patients, potentially causing substantial liabilities.

見通し

Grow LUPKYNIS Product Sales Ability to grow net product sales of LUPKYNIS remains a key forward-looking statement for overall financial performance.

Advance Aritinercept Development Plans include initiating a clinical study for Aritinercept in an additional autoimmune disease during the first half of 2026.

Capital Requirements Uncertainty Future funding needs are uncertain; potential need for additional financing could result in dilution or create operating restrictions.

Maintain Effective Internal Controls Management affirms commitment to maintaining effective internal control over financial reporting as of December 31, 2025.

同業比較

売上高 (TTM)

NVAX

$1.12B

+64.7%

BCRX

$874.84M

+94.1%

HRMY

$868.45M

+21.5%

粗利益率 (最新四半期)

SNDX

102.3%

-13.9pp

CLDX

100.0%

+0.0pp

ABCL

100.0%

+588.5pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
EWTX	$3.21B	-18.4	-32.0%	0.7%
VERA	$2.94B	-8.8	-59.7%	10.5%
RCUS	$2.29B	-6.9	-65.8%	8.7%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

7.3%

安定成長

4四半期純利益CAGR

108.2%

収益性の大幅な改善

キャッシュフロー安定性

100%

優れたキャッシュフローの実績

深度リサーチ

次回決算:2026年4月30日

EPS:$0.20

売上高:$76.98M

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし